Dr. Reddy's inches up on launching Abiraterone Acetate Tablets in US market

19 Jun 2020 Evaluate

Dr. Reddy's Laboratories is currently trading at Rs. 4008.55, up by 3.80 points or 0.09% from its previous closing of Rs. 4004.75 on the BSE.

The scrip opened at Rs. 4030.00 and has touched a high and low of Rs. 4044.90 and Rs. 3994.00 respectively. So far 14166 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4127.20 and Rs. 3954.20 respectively. The current market cap of the company is Rs. 66484.06 crore.

The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.

Dr. Reddy's Laboratories has launched Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food & Drug Administration (USFDA). The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

 

Dr. Reddys Lab Share Price

6290.55 73.40 (1.18%)
26-Apr-2024 13:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.15
Dr. Reddys Lab 6290.55
Cipla 1412.15
Zydus Lifesciences 948.00
Lupin 1621.35
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.